The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "interstitial lung disease"

Search results for: interstitial lung disease

Tips from a Cardiothoracic Radiologist: Interstitial Lung Disease & Radiology for the Rheumatologist

June 17, 2022 • By Samantha C. Shapiro, MD

Due to its array of radiographic patterns, interstitial lung disease can be challenging to diagnose and treat. Adam Guttentag, MD, a cardiothoracic radiologist, shared tips for ordering and interpreting chest computed tomography.... [Read More]

Filed Under: Conditions, Meeting Reports Tagged With: ACR Education Exchange, computed tomography, connective tissue disease, CT scan, CTD-ILD, ILD, interstitial lung disease (ILD), lungs, Radiologist, Vasculitis

Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

June 15, 2022 • By Samantha C. Shapiro, MD

No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients. ... [Read More]

Filed Under: Conditions, Scleroderma Tagged With: ILD, interstitial lung disease (ILD), lungs, nintedanib, Scleroderma, SSc-ILD, systemic sclerosis (SSc), tocilizumab

Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

December 1, 2021 • By Jason Liebowitz, MD

ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of… [Read More]

Filed Under: ACR Convergence, Conditions, Meeting Reports, Scleroderma Tagged With: ACR Convergence 2021, connective tissue disease, interstitial lung disease (ILD), nintedanib

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

September 22, 2021 • By Lara C. Pullen, PhD

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study. ... [Read More]

Filed Under: Conditions, DMARDs & Immunosuppressives Tagged With: interstitial lung disease (ILD), systemic sclerosis (SSc), systemic sclerosis-associated ILD, tocilizumab

Case Report: Rapidly Progressive Interstitial Lung Disease in a 6-Year-Old

April 17, 2021 • By Anusha Vuppala, MD, & Sarwat Umer, MD

Clinically amyopathic dermatomyositis (CADM), a rare subset of dermatomyositis (DM), is an autoimmune disease characterized by cutaneous findings of typical DM without evidence of myositis. Childhood presentation of CADM is rare, and not many studies describe the epidemiology of juvenile CADM.1,2 Although lung disease is rare among patients with juvenile DM, a few reports have… [Read More]

Filed Under: Conditions Tagged With: Clinically Amyotrophic Dermatomyositis (CADM), dermatomyositis, interstitial lung disease (ILD), juvenile dermatomyositis, Pediatric Rheumatology

Exploring Leflunomide’s Role in RA with Interstitial Lung Disease

September 11, 2020 • By Rajandeep Paik, MD, FACR

Interstitial lung disease (ILD) is a hetero­geneous group of lung paren­chymal disorders that share several clinical, radiologic and histopathologic features, and are therefore grouped together.1 ILD can occur in association with most rheumatic connective tissue diseases (CTDs), but patients with systemic sclerosis, polymyositis, dermatomyositis and rheumatoid arthritis have the highest risk of developing ILD.2 A… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: interstitial lung disease (ILD), leflunomide

Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

October 18, 2019 • By Jason Liebowitz, MD

MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: 2019 EULAR Congress, Interstitial Lung Disease

Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease

October 7, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to… [Read More]

Filed Under: Conditions Tagged With: biopsy, Interstitial Lung Disease, lung, transbronchial lung cryobiopsy (TBLC)

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

October 2, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in… [Read More]

Filed Under: Drug Updates Tagged With: ILD, Interstitial Lung Disease, lung disease, lungs, nintedanib

Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

July 1, 2019 • By Lara C. Pullen, PhD

A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…... [Read More]

Filed Under: Conditions

  • 1
  • 2
  • 3
  • …
  • 21
  • Next Page »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)